Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2801 - 2900
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2801 | 26641569 |
US |
51 | 2 |
Psoriasis, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2802 | 26641576 |
US |
60 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2803 | 26641603 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2804 | 26641607 |
US |
52 | 2 |
Rash erythematous, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2805 | 26641622 |
US |
19 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2806 | 26641627 |
US |
36 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2807 | 26641631 |
US |
3 | 1 |
Dermatitis atopic, Rash, Pruritus, Dry skin, Skin fissures, |
||||
DUPILUMAB, |
||||
| 2808 | 26641647 |
US |
22 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2809 | 26641677 |
US |
53 | 2 |
Pruritus, Sleep disorder due to a general medical condition, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2810 | 26641682 |
US |
32 | 2 |
Eczema, Skin irritation, Skin swelling, Rash, Pruritus, Dermatitis atopic, Rash, Rash pruritic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2811 | 26641728 |
US |
2 | 1 |
Inflammation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2812 | 26641740 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, CHORIOGONADOTROPIN ALFA, |
||||
| 2813 | 26641746 |
US |
77 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2814 | 26641752 |
US |
33 | 1 |
Anxiety, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2815 | 26641755 |
US |
2 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2816 | 26641808 |
US |
67 | 2 |
Skin haemorrhage, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2817 | 26641880 |
US |
36 | 1 |
Dermatitis atopic, Erythema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2818 | 26641881 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2819 | 26641885 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2820 | 26641979 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2821 | 26641980 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2822 | 26641983 |
US |
59 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2823 | 26641987 |
US |
10 | 2 |
Thirst, Polydipsia, Dysuria, Localised infection, Pyrexia, Hyperhidrosis, Sleep disorder, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2824 | 26642008 |
US |
14 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2825 | 26642015 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2826 | 26642063 |
US |
30 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2827 | 26642067 |
US |
2 | |
Dermatitis atopic, Rash, Discomfort, Product dose omission issue, |
||||
DUPILUMAB, SERTRALINE, SPIRONOLACTONE, |
||||
| 2828 | 26642137 |
US |
35 | 2 |
Dermatitis atopic, Rash, Discomfort, Sleep disorder due to a general medical condition, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2829 | 26642157 |
US |
17 | 2 |
Scratch, Skin haemorrhage, Rash, Product dose omission issue, Urticaria, Dermatitis atopic, Pruritus, Skin burning sensation, Skin exfoliation, Swelling face, Eye swelling, Ocular hyperaemia, Pyrexia, Dysphonia, Insomnia, Eczema, Dry skin, Erythema, Skin fissures, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, CALAMINE, ZINC OXIDE, FERRIC OXIDE RED, CALAMINE AND ZINC OXIDE, CALAMINE 8% AND ZINC OXIDE 8%, CALAMINE, PRAMOXINE HCL, CALAMINE 8%, ZINC OXIDE 8%, CALAMINE, PRAMOXIND HCL, CALAMINE, |
||||
| 2830 | 26642201 |
US |
69 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2831 | 26642205 |
US |
35 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2832 | 26642214 |
US |
2 | |
Inflammation, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, CETIRIZINE HCL, CETIRIZINE, DAPSONE GEL, 5%, DAPSONE, DASPONE, METRONIDAZOLE, METRONIDAZOLE TOPICAL, ERGOCALCIFEROL, |
||||
| 2833 | 26642228 |
US |
74 | 2 |
Dermatitis atopic, Rosacea, |
||||
DUPILUMAB, |
||||
| 2834 | 26642232 |
US |
16 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, TRALOKINUMAB-LDRM, |
||||
| 2835 | 26642272 |
US |
64 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2836 | 26642280 |
US |
27 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2837 | 26642283 |
US |
31 | 2 |
Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 2838 | 26642284 |
US |
60 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2839 | 26642290 |
US |
74 | 1 |
Dermatitis atopic, Drug effect less than expected, |
||||
DUPILUMAB, |
||||
| 2840 | 26642293 |
US |
66 | 2 |
Injection site pain, Upper limb fracture, Herpes virus infection, Pain in extremity, Diarrhoea, Eczema, Incorrect route of product administration, Inappropriate schedule of product administration, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2841 | 26642297 |
US |
52 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2842 | 26642298 |
US |
9 | 2 |
Dermatitis acneiform, Product dose omission issue, Pigmentation disorder, Acne, Lip dry, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2843 | 26642330 |
US |
6 | 2 |
Dermatitis atopic, Rash, Pruritus, Sleep disorder due to a general medical condition, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2844 | 26642338 |
US |
1 | |
Sleep disorder due to a general medical condition, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2845 | 26642345 |
US |
62 | 2 |
Stress, Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 2846 | 26642346 |
US |
15 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2847 | 26642357 |
US |
46 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2848 | 26642365 |
US |
48 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2849 | 26642452 |
US |
37 | 2 |
Pruritus, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2850 | 26642461 |
US |
26 | 2 |
Injection site erythema, Injection site swelling, Incorrect route of product administration, Inappropriate schedule of product administration, Eye swelling, Rash, Ocular hyperaemia, Dry skin, Eczema, Dermatitis atopic, Eye pruritus, Dry eye, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2851 | 26642469 |
US |
45 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2852 | 26642470 |
US |
33 | 2 |
Dermatitis atopic, Exposure during pregnancy, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2853 | 26642491 |
US |
1 | |
Eye allergy, Eye pruritus, Eye swelling, Ocular hyperaemia, Dry skin, Eye inflammation, Dry eye, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2854 | 26642495 |
US |
47 | 2 |
Hypersensitivity, Immunology test abnormal, Product use in unapproved indication, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2855 | 26642498 |
US |
35 | 2 |
Dermatitis atopic, Product storage error, |
||||
DUPILUMAB, |
||||
| 2856 | 26642499 |
US |
48 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2857 | 26642504 |
US |
29 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2858 | 26642554 |
US |
18 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2859 | 26642558 |
US |
39 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2860 | 26642559 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2861 | 26642874 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2862 | 26642883 |
US |
5 | 2 |
Pruritus, Dermatitis atopic, Therapeutic response shortened, Product use in unapproved indication, Nasopharyngitis, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2863 | 26642897 |
US |
57 | 2 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 2864 | 26642902 |
US |
75 | 1 |
Pruritus, Dermatitis atopic, Rash, |
||||
DUPILUMAB, DUPILUMAB, ALBUTEROL SULFATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, GARLIC, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MAGNESIUM, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE INHALATION SPRAY, ERGOCALCIFEROL, |
||||
| 2865 | 26642958 |
US |
8 | 1 |
Dyspnoea, Dry skin, Dermatitis atopic, Therapeutic response decreased, Burning sensation, Rash, Injection site pain, |
||||
DUPILUMAB, ALBUTEROL SULFATE, LORATADINE, LORATADINE TABLET, GUANFACINE HYDROCHLORIDE, GUANFACINE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, CETIRIZINE HYDROCHLORIDE, |
||||
| 2866 | 26642973 |
US |
41 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2867 | 26642996 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2868 | 26642998 |
US |
49 | 1 |
Abdominal discomfort, Dermatitis atopic, Arthralgia, Skin fissures, Lymphadenopathy, Arthropathy, Product dose omission issue, |
||||
DUPILUMAB, ESOMEPRAZOLE MAGNESIUM, ACETAMINOPHEN, ASPRIN, CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID), CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID), AND CAFFEINE, ACETAMINOPHEN, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ACETAMINOPHEN, CAFFEINE, |
||||
| 2869 | 26643005 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2870 | 26643025 |
US |
48 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2871 | 26643065 |
US |
83 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2872 | 26643071 |
US |
1 | |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2873 | 26643075 |
US |
2 | |
Dermatitis atopic, Erythema, Skin irritation, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, |
||||
| 2874 | 26643095 |
US |
2 | |
Psoriasis, Dermatitis atopic, |
||||
DUPILUMAB, ALBUTEROL SULFATE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 2875 | 26643164 |
US |
26 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2876 | 26643165 |
US |
50 | 2 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 2877 | 26643187 |
US |
15 | 2 |
Dermatitis atopic, Drug dose omission by device, Injection site pain, |
||||
LEBRIKIZUMAB-LBKZ, LEBRIKIZUMAB-LBKZ, |
||||
| 2878 | 26643290 |
US |
9 | 1 |
Dermatitis atopic, Dry skin, Skin irritation, Skin fissures, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2879 | 26643291 |
US |
59 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2880 | 26643301 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2881 | 26643309 |
US |
2 | |
Psoriasis, Pruritus, Nausea, Headache, Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, |
||||
| 2882 | 26643381 |
US |
35 | 2 |
Dermatitis atopic, Neurodermatitis, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2883 | 26643411 |
US |
37 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2884 | 26643632 |
US |
18 | 1 |
Dermatitis atopic, Pruritus, Skin exfoliation, Dry skin, Injection site pain, Treatment noncompliance, |
||||
DUPILUMAB, ALBUTEROL SULFATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, LISDEXAMFETAMINE DIMESYLATE, |
||||
| 2885 | 26643634 |
US |
2 | |
Rash erythematous, Dermatitis atopic, |
||||
DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AZELASTINE HYDROCHLORIDE, AZELASTINE, CALCIUM, CARVEDILOL, ESCITALOPRAM OXALATE, ESCITALOPRAM, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, GABAPENTIN, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, HYOSCYAMINE SULFATE, LAMOTRIGINE, LOSARTAN POTASSIUM, LOSARTAN, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, TIRZEPATIDE, NYSTATIN, NYSTATIN OINTMENT, NYSTATIN CREAM, EVOLOCUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 2886 | 26643766 |
US |
54 | 2 |
Dermatitis atopic, Pruritus, Skin fissures, Skin exfoliation, Dry skin, Eczema, Therapeutic response decreased, |
||||
DUPILUMAB, OMEPRAZOLE MAGNESIUM, |
||||
| 2887 | 26643928 |
JP |
||
Erythema multiforme, Dermatitis atopic, Off label use, |
||||
| 2888 | 26645860 |
US |
14 | 2 |
Necrotising fasciitis, Lip dry, Pain of skin, Sleep disorder, Skin fissures, Blister, Therapeutic product effect decreased, Skin exfoliation, Dermatitis atopic, Dry skin, Influenza, Skin burning sensation, Erythema, |
||||
UPADACITINIB, UPADACITINIB, |
||||
| 2889 | 26646004 |
US |
||
Food allergy, Dermatitis atopic, Foetal exposure during pregnancy, |
||||
INFLIXIMAB-DYYB, |
||||
| 2890 | 26639681 |
US |
72 | 2 |
Skin swelling, Pain of skin, Pruritus, Ocular hyperaemia, Arthralgia, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2891 | 26639730 |
US |
4 | 2 |
Asthma, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2892 | 26639736 |
US |
33 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2893 | 26639738 |
US |
80 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2894 | 26639750 |
US |
69 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2895 | 26639759 |
US |
12 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2896 | 26638233 |
US |
52 | 2 |
Diabetes mellitus, Peripheral swelling, Swelling face, Pyrexia, Rash, Eczema, Swelling, Pruritus, Scab, Skin hypertrophy, Skin irritation, Blood triglycerides increased, Thyroid disorder, Dermatitis atopic, Injection site pain, |
||||
DUPILUMAB, |
||||
| 2897 | 26633901 |
US |
58 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2898 | 26633911 |
US |
18 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2899 | 26633933 |
US |
32 | 2 |
Dermatitis atopic, Rash macular, |
||||
DUPILUMAB, |
||||
| 2900 | 26634475 |
US |
2 | |
Dermatitis atopic, |
||||
OMALIZUMAB, OMALIZUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30